CAHC’s Joel White teamed with Hannah Anderson, senior director of policy for the Center for a Healthy America at AFPI, on an op-ed published in The Hill.
The op-ed argues that the Inflation Reduction Act’s Medicare drug pricing provisions are restricting access to some medicines while contributing to higher premiums and out-of-pocket costs, citing elevated prescription rejection rates for drugs subject to negotiation. Joel and Hannah contend that Congress should reconsider the law’s price controls and Part D changes, which they say have shifted costs to insurers, taxpayers, and patients while potentially discouraging development of new treatments.